Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Common Equity (2020 - 2025)

Historic Common Equity for Universe Pharmaceuticals (UPC) over the last 6 years, with Q3 2025 value amounting to $56.1 billion.

  • Universe Pharmaceuticals' Common Equity rose 2335.36% to $56.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $56.1 billion, marking a year-over-year increase of 2335.36%. This contributed to the annual value of $56.1 billion for FY2025, which is 2335.36% up from last year.
  • Per Universe Pharmaceuticals' latest filing, its Common Equity stood at $56.1 billion for Q3 2025, which was up 2335.36% from $45.5 billion recorded in Q3 2024.
  • In the past 5 years, Universe Pharmaceuticals' Common Equity ranged from a high of $56.1 billion in Q3 2025 and a low of $47.0 million during Q3 2021
  • Its 5-year average for Common Equity is $33.0 billion, with a median of $35.3 billion in 2022.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 7508363.91% in 2022, then crashed by 2083.29% in 2023.
  • Universe Pharmaceuticals' Common Equity (Quarter) stood at $47.0 million in 2021, then surged by 75083.64% to $35.3 billion in 2022, then decreased by 20.83% to $28.0 billion in 2023, then surged by 62.68% to $45.5 billion in 2024, then rose by 23.35% to $56.1 billion in 2025.
  • Its Common Equity stands at $56.1 billion for Q3 2025, versus $45.5 billion for Q3 2024 and $28.0 billion for Q3 2023.